NCT00153634: Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Summary

This was a randomized multi-center clinical trial to compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P. aeruginosa sputum isolates to guide antibiotic selection for treatment of airway infection in clinically stable patients with CF.

Timeline

Start: 2004-03
Primary completion: —
Completion: 2007-11

Publications

Background Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May;42(5):1915-22. doi: 10.1128/JCM.42.5.1915-1922.2004.
Background Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother. 2005 Nov;56(5):879-86. doi: 10.1093/jac/dki338. Epub 2005 Sep 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amikacin	Small molecule	5 mg/kg	Intravenous
Subject	Amikacin	Small molecule	7.5 mg/kg	Intravenous
Subject	Azithromycin	Small molecule	250 mg	Oral
Subject	Ceftazidime	Small molecule	50 mg/kg	Intravenous
Subject	Ciprofloxacin	Small molecule	500 mg	Oral
Subject	Ciprofloxacin	Small molecule	750 mg	Oral
Subject	Meropenem	Small molecule	40 mg/kg	Intravenous
Subject	Piperacillin-tazobactam	Unknown	100 mg/kg	Intravenous
Subject	Tobramycin	Unknown	2.5 mg/kg	Intravenous
Subject	Tobramycin	Unknown	3.3 mg/kg	Intravenous
Subject	ticarcillin-clavulanate	Unknown	100 mg/kg	Intravenous

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Summary

Timeline

Publications

Drugs

Indications